Since there exists uncertainty regarding the effectiveness of local surgery for bone metastases (BM) originating from renal cell carcinoma (RCC), researchers assessed the outcomes of Chinese patients with RCC and BM, for the first time ever, in this study.
This study involved 168 patients managed for RCC and BM at Changzheng Hospital in Shanghai, China, between March 2009 and December 2018. In the study cohort, the median overall survival (OS) was estimated to be 43 months. The 1‐year, 3‐year, and 5‐year survival rates following surgery were estimated to be 77.4%, 55.9%, and 31.8%, respectively.
The number of preoperative metastatic sites, International Metastatic Renal Cell Carcinoma Database Consortium risk score, and Memorial Sloan Kettering Cancer Center score were identified as independent predictors of OS, on multivariable Cox regression. Careful patient selection for local surgery was shown to have paramount significance. Experts observed much worse prognoses of patients in the Memorial Sloan Kettering Cancer Center–based and International Metastatic Renal Cell Carcinoma Database Consortium–based poor‐risk groups vs those of the intermediate‐risk groups. “Stratified treatment” can be implemented as per these criteria, in the current clinical practice.